A Deeper Dive: Patient Perceptions of Burden and Satisfaction with Current and Emerging Psoriatic Therapies

Introduction:Current and emerging systemic therapies are expanding treatment options for moderate-to-severe plaque psoriasis. Real-world usage, however, is influenced by patient-perceived treatment burden. Here, results from the 2026 cross-sectional Systemic Perceptions Survey of the National Psoriasis Foundation patient community are reported. Materials and Methods: Adults aged ≥21 years who self-reported clinician diagnosed moderate-to-severe plaque psoriasis with possible concomitant psoriatic arthritis and a prescription for psoriasis therapy within the past 12 months were included. Treatment burden and preference were assessed. Results: Among 270 participants, 54.8% had psoriasis only and 45.2% had concomitant psoriatic arthritis. Patients on biologics reported higher satisfaction with disease control (94%) compared to oral-only (70%) and topical-only patients (54%). When asked about a biologic that offered greater skin clearance, 69% would try a biologic, 17% preferred an oral medication, and 13% preferred a topical. Patients on biologics rated frequency of use as the least burdensome of all assessed burden dimensions, while those on topicals and orals rated it much higher. A biologic administered once or twice yearly with a high chance of disease clearance was the preferred treatment option for 68% of patients, compared to daily orals (22%) and topicals (10%). Patients preferred fixed-dosing intervals (76%) over as-needed dosing (24%). Additionally, 61% defined “remission” as sustained clear skin while on treatment, suggesting patients are not expecting to come off therapy. Conclusion: Patient preferences extend beyond route of administration, with many favoring long-interval biologics when infrequent dosing and high clearance are considered. These findings highlight the importance of balancing treatment burden alongside efficacy and patient expectations for on-treatment remission.